Patients with cancer can be at high risk of severe COVID-19 due to their age, disease, cancer treatment, and medical co-morbidities.1 The pandemic has also led to substantial disruptions to diagnosis and treatment in many parts of the world.2,3 Patients with cancer in low-income and middle-income countries (LMICs) are further disadvantaged compared with those in high-income settings because of…
In March, 2024, an Advisory Group of 28 independent scientists from 22 countries met in Lyon, France to recommend priorities for carcinogenicity evaluations by the…
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved PSA progression-free survival providing evidence of enhanced anticancer activity in patients with metastatic castration-resistant prostate cancer with risk…
People with cancer have a higher risk of mortality from COVID-19 than those without cancer. Patients younger than 50 years with cancer treatment have the…
In March, 2024, an Advisory Group of 28 independent scientists from 22 countries met in Lyon, France to recommend priorities for carcinogenicity evaluations by the…
Cabozantinib in advanced adrenocortical carcinoma showed promising efficacy with a manageable and anticipated safety profile. Further prospective studies with cabozantinib alone and in combination with…
Cabozantinib shows promising activity in patients with MPPGs.
Nivolumab monotherapy and nivolumab plus ipilimumab combination therapy showed promise in the CheckMate 358 study as potential treatment options for recurrent or metastatic cervical cancer.…
In May, 2023, a 56-year-old woman was referred to the Centre Léon Bérard (Lyon, France) with dry cough, chest pain, pelvic pain, and skin lesions.…
Correlations of overall response rate and progression-free survival with overall survival were generally moderate in this pooled analysis. The findings support routine analysis of mature…
Dr Bernardo Goulart (US Food and Drug Administration) discusses his paper on correlations of response rate and progression-free survival with overall survival in immunotherapy trials…
